Document Type : Original Article
Authors
1 Assistant Professor of Ophthalmology, Department of Ophthalmology, Baqiyatallah University of Medical Sciences, Tehran, Iran
2 Associate Professor of Ophthalmology, Department of Ophthalmology, Baqiyatallah University of Medical Sciences, Tehran, Iran
3 3Research Associate, Department of Ophthalmology, Bina Eye Hospital Research Center, Tehran, Iran
4 Department of Ophthalmology, Bina Eye Hospital Research Center, Tehran, Iran
Abstract
Keywords
Open Access Policy: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/
1.Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581-611. [PubMed: 15294883]. https://doi.org/10.1210/er.2003-0027 PMid:15294883 |
||||
2. Thompson JT, de Bustros S, Michels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic traction retinal detachment of the macula. Arch Ophthalmol. 1987;105(4):497-502. [PubMed: 2436603]. https://doi.org/10.1001/archopht.1987.01060040067035 PMid:2436603 |
||||
3. Tolentino FI, Cajita VN, Gancayco T, Skates S. Vitreous hemorrhage after closed vitrectomy for proliferative diabetic retinopathy. Ophthalmology. 1989;96(10):1495-500. [PubMed: 2587044]. https://doi.org/10.1016/S0161-6420(89)32700-X PMid:2587044 |
||||
4. Schachat AP, Oyakawa RT, Michels RG, Rice TA. Complications of vitreous surgery for diabetic retinopathy. Ophthalmology. 1983;90(5):522- 30. https://doi.org/10.1016/S0161-6420(83)34540-1 PMid:6192378 |
||||
5. Novak MA, Rice TA, Michels RG, Auer C. Vitreous hemorrhage after vitrectomy for diabetic retinopathy. Ophthalmology. 1984;91(12):1485-9. [PubMed: 6521989]. https://doi.org/10.1016/S0161-6420(84)34099-4 PMid:6521989 |
||||
6. Blankenship GW. Management of vitreous cavity hemorrhage following pars plana vitrectomy for diabetic retinopathy. Ophthalmology. 1986;93(1):39-44. [PubMed: 2419815]. https://doi.org/10.1016/S0161-6420(86)33791-6 PMid:2419815 |
||||
7. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. 2006;26(6):699-700. [PubMed: 16829817]. https://doi.org/10.1097/01.iae.0000225351.87205.69 PMid:16829817 |
||||
8. Khafagy A. Role of adjunctive use of intravitreal bevacizumab for severe proliferative diabetic retinopathy before vitrectomy. Med J Cairo Univ. 2011;79(2). | ||||
9. Ghasemi Falavarjani K, Hashemi M, Modarres M, Hadavand Khani A. Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy. Eye (Lond). 2014;28(5):576-80. [PubMed: 24556886]. https://doi.org/10.1038/eye.2014.21 PMid:24556886 PMCid:PMC4017106 |
||||
10. Yeh PT, Yang CH, Yang CM. Intravitreal bevacizumab injection for recurrent vitreous haemorrhage after diabetic vitrectomy.Acta Ophthalmol. 2011;89(7):634-40. [PubMed: 20064118]. https://doi.org/10.1111/j.1755-3768.2009.01821.x PMid:20064118 |
||||
11. Ishikawa K, Honda S, Tsukahara Y, Negi A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye (Lond). 2009;23(1):108-11. [PubMed: 17891057]. https://doi.org/10.1038/sj.eye.6702983 PMid:17891057 |
||||
12. Abu El-Asrar AM, Al-Bishi SM, Kangave D. Outcome of temporary silicone oil tamponade in complex rhegmatogenous retinal detachment. Eur J Ophthalmol. 2003;13(5):474-81. [PubMed: 12841571]. https://doi.org/10.1177/112067210301300509 PMid:12841571 |
||||
13. Ghazi NG, Green WR. Pathology and pathogenesis of retinal detachment. Eye (Lond). 2002;16(4):411-21. [PubMed: 12101448]. https://doi.org/10.1038/sj.eye.6700197 PMid:12101448 |
||||
14. Xu Y, You Y, Du W, Zhao C, Li J, Mao J, et al. Ocular pharmacokinetics of bevacizumab in vitrectomized eyes with silicone oil tamponade. Invest Ophthalmol Vis Sci. 2012;53(9):5221-6. [PubMed: 22786911]. https://doi.org/10.1167/iovs.12-9702 PMid:22786911 PMCid:PMC3416031 |
||||
15. Sivak-Callcott JA, O'Day DM, Gass JD, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001;108(10):1767-76. [PubMed: 11581047] quiz1777, 1800. https://doi.org/10.1016/S0161-6420(01)00775-8 PMid:11581047 |
||||
16. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008;115(9):1571-80. [PubMed: 18440643] 1580 e1-3. https://doi.org/10.1016/j.ophtha.2008.02.026 PMid:18440643 |
||||
17. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142(1):155-8. [PubMed: 16815267]. https://doi.org/10.1016/j.ajo.2006.02.015 PMid:16815267 |
||||
18. Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology. 2009;116(10):1943-8. [PubMed: 19699531]. https://doi.org/10.1016/j.ophtha.2009.07.001 PMid:19699531 |
||||
19. Lo WR, Kim SJ, Aaberg TM Sr, Bergstrom C, Srivastava SK, Yan J, et al. Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin). Retina. 2009;29(7):926-31. [PubMed: 19584650]. https://doi.org/10.1097/IAE.0b013e3181a8eb88 PMid:19584650 PMCid:PMC3033782 |
||||
20. Yeh PT, Yang CM, Lin YC, Chen MS, Yang CH. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina. 2009;29(6):768-74. [PubMed: 19516117]. https://doi.org/10.1097/IAE.0b013e3181a3b7ef PMid:19516117 |
||||
21. Sawada O, Kawamura H, Kakinoki M, Sawada T, Ohji M. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol. 2007;125(10):1363-6. [PubMed: 17923544]. 4 Razavi Int J Med. 2017; 5(2):e43217. Alishiri A et al. https://doi.org/10.1001/archopht.125.10.1363 PMid:17923544 |
||||
22. Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92(2):213-6. [PubMed: 17965108]. https://doi.org/10.1136/bjo.2007.127142 PMid:17965108 |
||||
23. Jampol LM, Shankle J, Schroeder R, Tornambe P, Spaide RF, Hee MR. Diagnostic and therapeutic challenges. Retina. 2006;26(9):1072-6. [PubMed: 17151497]. https://doi.org/10.1097/01.iae.0000248819.86737.a5 PMid:17151497 |
||||
24. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina. 2006;26(9):1006-13. [PubMed: 17151487]. https://doi.org/10.1097/01.iae.0000246884.76018.63 PMid:17151487 |
||||
25. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113(10):1695 e1- 15. [PubMed: 17011951]. https://doi.org/10.1016/j.ophtha.2006.05.064 PMid:17011951 |